Surgery remains the only curative treatment for pancreatic cancer; however, majority of patients present with advanced unresectable disease upon diagnosis. Treatment of nonmetastatic, locally advanced pancreatic cancer (LAPC) continues to require multidisciplinary bimodality or trimodality approach. Neoadjuvant therapies have been investigated for LAPC given its established role in other solid ...

Because patients with locally advanced rectal cancer are at high risk for both recurrence and distant disease, they require adjuvant therapy. In the United States, the current standard of care is neoadjuvant chemoradiation followed by surgery and adjuvant chemotherapy. Neoadjuvant chemoradiation has been shown to improve local recurrence rates and decrease toxicity. However in the era of total ...

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment efficacy with smaller patient accruals and over ...

Immunotherapy has been a revolution in cancer management the metastatic setting. This led to prompt evaluation of such therapies earlier stages. article discusses still limited amount data finding rationale assess therapy this setting and reviews preclinical clinical available. Overall, neoadjuvant immunotherapy is promising approach for treatment cancers supporting its use strong. Neoadjuvant ...

Breast cancer accounts for the majority of cancers in women worldwide, and most common overall UK. It is typically treated by a combination surgical medical therapies, which commonly include neoadjuvant and/or adjuvant chemotherapy. Neoadjuvant chemotherapy favour alongside surgery treatment breast confers no disease-free survival advantage. Nonetheless, favoured as first line therapy cancer. T...

OBJECTIVE Molecular characterization of ameloblastoma has indicated a high frequency of driver mutations in BRAF and SMO. Preclinical data suggest that Food and Drug Administration-approved BRAF-targeted therapies may be immediately relevant for patients with ameloblastoma positive for the BRAF V600E mutation. METHODS A neoadjuvant treatment regime of dabrafenib was given to a patient with re...

Effective treatment of advanced metastatic disease remains the primary challenge in the management of inoperable pancreatic cancer. Current therapies such as oxaliplatin (OxPt)-based chemotherapy regimens (FOLFIRINOX) provide modest short-term survival improvements, yet with significant toxicity. Photodynamic therapy (PDT), a light-activated cancer therapy, demonstrated clinical promise for pan...